Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
Finncap's revenue forecasts were upgraded by 6% and 7% to £72.2mln and £79.5mln for the full year 2017 and 2018 respectively.
In the nine months since the stock listed last September, InnovaDerma’s shares have surged by over 300p, or 400%, on the back of the success of its ridiculously popular Skinny Tan range
Citi has gone to ‘neutral’ from ‘buy’ on GSK shares, which it reckons are worth £17 each
The digital platform will be used collate both positron emission tomography (PET) and MRI scans from centres across Europe
The ImmunoBody technology was used to develop SCIB1 and SCIB2 – the company’s leading drug candidates.
Seppo Mäkinen, Dr Ajay Agrawal and Andrew King bring with them a wealth of industry and commercial experience
Dr David Huang will present at IDWeek 2017 on October 7 where he will give an overview of the REVIVE-1 phase-III clinical study
Last month the company received a boost in the form of “constructive feedback” from regulators in both the UK and US reviewing the clinical trial requirements for MED2002.
Two companies, three wells
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.